You are a consultant working for a firm helping customers transform their businesses and drive meaningful impact. At the morning huddle meeting, your boss shares a few new clients your firm recently engaged with. You get a pick of the company, so your first task is to select who you’d like to work with.
All these clients have already completed the B Impact Assessment, which they shared with you (you will find a link to the assessment by clicking on the company in the Company Selection assignment). What they are looking to do now is to drive the score improvement.
Your goal is to familiarize yourself with the current state, identify ONE improvement area you will focus on, and develop a change management and an impact improvement plan to help your client improve its impact assessment score in the chosen area.
Nutrition variables were assessed in each group and are presented in Table 2. Mean daily energy intake was compared with the energy calculated by 25kcal/kg ideal body weight formula. No significant difference existed between the groups for energy intake. Weight loss in the taurine group was significantly lower than the control group (p = 0.050). NUTRIC score showed no significant difference between groups (p = 0.402). Table 3 shows the levels of serum IL-6, IL-10, TNF-a, and hs-CRP at the beginning and end of study in both groups. As can be observed, a significant difference exists in the serum levels of IL-6 between two groups at the end of the study (p = 0.038). Although the serum levels of hs-CRP and IL-10 showed higher reduction in the taurine group, this differencea were not significant (p = 0.239 and p = 0.802, respectively). TNF-a showed higher increase in the control group but no significant difference was observed between the groups at the end of the study (p = 0.073). Clinical outcomes are presented in Table 4. At the beginning of the study, no significant difference existed between the groups in GCS, APACHEll, and SOFA scores. At the end of the study, a significant difference was observed in GCS and APACHEll scores in two groups (p = 0.028 and p = 0.049, respectively). Although mortality rate and ventilator dependency duration in the taurine group were less than the control group, this difference was not significant (p = 0.240 and p = 0.215, respectively). Also, no difference was observed between the groups in length of ICU stay (p = 0.963). The present study was a double-blind randomized clinical trial to determine the effect of taurine on patients with traumatic brain injury fed through enteral route. Generally, patients who received taurine showed better clinical outcomes compared with the patients who did not receive taurine. About the safety of the of taurine used in the present study, it is reported that 3-6 g/day taurine for one year does not have any harmful effects on the health (31) and about the effectiveness, Elmokadem et al. (29) suggested that in critically ill septic patients, 30 mg/kg/day taurine reduces IL-6 (as an important marker of immune and inflammatory response in the central nervous system). Therefore, based on the evidence, we decided to administer 30 mg/kg/day with the maximum dose of 3 g/day of taurine.>GET ANSWER